Loading...
Only a minority of thyroid cancer patients develop locally recurrent or metastatic disease that is not curable with local therapy or I-131 treatment. However, treatment options for this small cohort have been limited; the only FDA-approved chemotherapy agent for thyroid cancer is adriamycin, which has shown only modest efficacy. Fortunately, our understanding of thyroid cancer’s underlying biology has grown dramatically during the past decade, and this advancement has opened the way to investigation of targeted agents and identification of new therapies. Researchers now report results of two phase II studies of potentially active oral agents.
In one trial, investigators evaluated the efficacy of sorafenib (Nexavar), a multikinase inhibitor t…